BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, April 29, 2026
Home » Topics » Disease categories and therapies » Cancer

Cancer
Cancer RSS Feed RSS

Cancer cells being destroyed by immunotherapy
Immuno-oncology

Leukogene’s LTI-214 designated orphan drug for AML

Nov. 5, 2025
No Comments
Leukogene Therapeutics Inc.’s lead product candidate LTI-214 (M2T-CD33) has been awarded orphan drug designation by the FDA for the treatment of acute myeloid leukemia (AML).
Read More

Celltrion, Portrai in $87M R&D deal to discover new drug targets

Nov. 4, 2025
By Marian (YoonJee) Chu
No Comments
Celltrion Inc. announced Oct. 29 the signing of an $87.75 million joint drug R&D agreement with AI and spatial transcriptome-based biotech Portrai Inc.
Read More
Illustration of nasopharyngeal carcinoma

Lepu’s MRG-003 cleared as China’s first EGFR ADC for advanced NPC

Nov. 4, 2025
By Marian (YoonJee) Chu
No Comments
Lepu Biopharma Co. Ltd. said Oct. 30 it won Chinese approval of a novel antibody-drug conjugate (ADC), Meiyouheng (becotatug vedotin injection), making it China’s first epidermal growth factor receptor (EGFR)-directed ADC for advanced nasopharyngeal cancer (NPC).
Read More
Stock chart, red down arrow

Incyte aboard, SMARCA2 shift by Prelude enshrouds Foghorn

Nov. 4, 2025
By Randy Osborne
No Comments
Just as investors were looking ahead to news by year-end on Prelude Therapeutics Inc.’s SMARCA2-targeted degraders, the firm said work in the space will be halted, with efforts shifting toward the mutant selective JAK2V617F JH2 inhibitor program by way of a new deal with Incyte Corp.
Read More
Cancer

Innocare Pharma divulges new CBLB inhibitors

Nov. 4, 2025
Beijing Innocare Pharma Tech Co. Ltd. has synthesized E3 ubiquitin-protein ligase CBL-B (CBLB) inhibitors reported to be useful for the treatment of cancer.
Read More
Concept art for targeting cancer
Cancer

Astellas’ CRBN-based protein degrader inhibits KRAS G12D tumor growth

Nov. 4, 2025
No Comments
Researchers at Astellas Pharma Inc. have reported preclinical efficacy data of ASP-4396, a KRAS G12D degrader.
Read More
Acute myeloid leukemia
Immuno-oncology

Evaxion unveils EVX-04 for acute myeloid leukemia

Nov. 4, 2025
No Comments
Evaxion A/S has unveiled EVX-04, an AI-designed precision cancer vaccine candidate being developed for acute myeloid leukemia (AML).
Read More
Cancer

Covalent p53 activator shows activity in Y220C-mutant models

Nov. 4, 2025
No Comments
At the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Frontier Medicines Corp. presented a first-in-class covalent activator of p53 Y220C with high potency and selectivity in restoring p53 tumor suppressor function.
Read More
Immuno-oncology

Optimized arenaviruses with tumor-tropic mutations show preclinical activity

Nov. 4, 2025
No Comments
Oncolytic viruses are a potential therapeutic approach that uses viruses to selectively infect and kill cancer cells. In a new publication in Cell Reports Medicine, researchers from Heinrich-Heine-Universität Düsseldorf and Abalos Therapeutics GmbH show that tumor-tropic mutations in lymphocytic choriomeningitis virus (LCMV) enhance selective replication in cancer cells.
Read More

Stock turns sharply higher with Terns’ leukemia data

Nov. 3, 2025
By Lee Landenberger
No Comments
Early stage data from Terns Pharmaceuticals Inc.’s lead candidate showed a large reduction in the number of leukemia cells in those with previously treated chronic myeloid leukemia. Results from the ongoing phase I Cardinal study of TERN-701, an oral, allosteric BCR-ABL tyrosine kinase inhibitor, were “unprecedented,” according to Terns.
Read More
Previous 1 2 … 101 102 103 104 105 106 107 108 109 … 4109 4110 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 28, 2026.
  • Illustration of a tumor

    Detecting the invisible: minimal residual disease at AACR 2026

    BioWorld Science
    Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for April 28, 2026
  • Cerebral aneurysm illustration

    Grace Therapeutics hits CRL setback with GTx-104 despite positive trial

    BioWorld
    Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...
  • Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists

    BioWorld Science
    Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing